Background
==========

*Staphylococcus aureus*is a leading cause of nosocomial infections and has recently emerged as a community acquired pathogen \[[@B1]-[@B3]\]. *S. aureus*is also a paradigm of adaptive power to antimicrobial chemotherapy, able to develop resistance to virtually all classes of antibiotics \[[@B4]\].The acquisition of resistance to β-lactam antibiotics is particularly relevant in clinical terms. Although β-lactams (i.e. penicillin G) were the first class of large-spectrum antibiotics to be introduced into clinical practice, they are still the most widely used due to their high effectiveness, low cost, ease of delivery and minimal side effects \[[@B5]\].

In response to β-lactam chemotherapy, *S. aureus*has sequentially acquired two resistance genes: first *blaZ*, which codes for a β-lactamase and confers resistance to penicillins only, and then *mecA*, which codes for an extra penicillin-binding protein (PBP2a) with reduced affinity for virtually all β-lactams \[[@B6],[@B7]\]. The transcription of both resistance genes may be controlled by homologous two-component systems consisting on a sensor-inducer (BlaR1 and MecR1) and a repressor (BlaI and MecI). Interestingly, in spite of the cross-resistance to virtually all β-lactams provided by *mecA*, the great majority (\> 95%) of contemporary MRSA are still positive for the β-lactamase locus \[[@B8]\]. Moreover, the regulators of *blaZ*, BlaR1 and BlaI, can efficiently induce *mecA*transcription and, do it faster than the \"natural\" *mecA*regulators, MecR1 and MecI \[[@B9],[@B10]\]. In addition, since many MRSA strains do not have functional *mecI-mecR1*genes due to polymorphisms in the *mecA*regulatory region \[[@B11]\], the *mecA*transcription is presumably under the control of the *blaI-blaR1*genes only. In line with these observations, the presence of the *blaZ*locus has been shown to promote *mecA*acquisition and stabilization \[[@B12],[@B13]\].

In *S. aureus*, the β-lactamase genes may be located in a plasmid or mobilized into the chromosome by transposon Tn552 \[[@B14]\]. In contrast to the diversity of β-lactamase genes found in gram-negative bacteria, all staphylococcal enzymes studied so far are molecular class A serine β-lactamases placed in functional group 2a \[[@B8]\]. The mature form of the enzyme has a molecular mass of 30 kDa, contains 257 amino acids, and is secreted extracellularly \[[@B15]\]. In 1965, Richmond proposed the subdivision of staphylococcal β-lactamases in four serotypes \[[@B16]\], but the structural basis of the distinction between types is still uncertain and no clear relationship between sequence and serotype was found \[[@B17]\]. Interestingly, serotypes were shown to have specific geographic distributions \[[@B8]\], which may suggest a relationship between *bla-*type and genetic lineage. Recently, Olsen *et al*have studied the allelic variation of the *blaZ*gene among several staphylococcal species and 11 BlaZ protein types were identified \[[@B14]\]. The multiple-sequence alignment of those sequence types suggest a separate evolution for plasmid- and chromosomally-encoded *blaZ*and a very low frequency for exchange of the β-lactamase locus between strains and species.

In evolutionary terms, MRSA may be regarded as a recent sub-branch of the *S. aureus*population which has acquired the heterelogous chromosomal cassette containing the *mecA*gene - the SCC*mec*element \[[@B18]\]. Molecular epidemiology studies on large collections of MRSA isolates have clearly shown that MRSA has a strong clonal structure and that very few lineages, defined by specific macro-restriction patterns of chromosomal DNA and/or multi-locus sequence types, account for the great proportion of MRSA infections worldwide \[[@B19],[@B20]\]. The clonal structure of MRSA population may result from a \"host barrier\" for the *mecA*acquisition, which restricts the number of acquisitions to few more permissive lineages \[[@B13],[@B21]\] and/or from the clonal expansion of previously highly epidemic (MSSA) lineages, which have acquired the *mecA*gene. Recent data based on comparative genomics of MRSA lineages \[[@B22]-[@B24]\] supports both mechanisms as it seems that, within the same genetic (epidemic) lineage, SCC*mec*acquisitions may occur continuously at the local level.

In spite of the several lines of evidence suggesting an important role of the *bla*locus in the acquisition, stabilization and regulation of the *mecA*gene, the variability of *bla*genes at the sequence level has never been evaluated among pandemic MRSA lineages. The present study was conducted in order to evaluate the allelic variability of β-lactamase locus in a representative collection of internationally epidemic MRSA clones and also, for comparative purposes, in a diverse collection of methicillin-susceptible *S. aureus*strains (MSSA), in an attempt to make evolutionary correlations between β-lactamase allotypes and β-lactam resistance phenotypes (i.e. MRSA *vs*MSSA), SCC*mec*types and/or genetic lineages.

Methods
=======

Strain collection
-----------------

*S. aureus*strains used in the present study are listed in Tables [1](#T1){ref-type="table"} (MRSA) and [2](#T2){ref-type="table"} (MSSA). All strains have been previously assigned to genetic lineages by Pulse-field gel electrophoresis (PFGE), multi-locus sequence typing (MLST) and protein A sequence typing (*spa*typing). MRSA strains have been additionally characterized in terms of their SCC*mec*types. The presence of a functional β-lactamase locus was confirmed by nitrocefin disks (Sigma) for all strains, in the presence and absence of an inducer (oxacillin at 0.05 mg/L).

###### 

Characteristics and *bla*locus allotypes of the MRSA strains used in this study

  **Clonalcomplex ^a)^**   MLST (ST)   SCC*mec*type   Strain        Isolation origin   Isolation year   *bla*locus alleles   **Ref**.        
  ------------------------ ----------- -------------- ------------- ------------------ ---------------- -------------------- ---------- ---- --------------------------
                           247         I              E2125         Denmark            1964             1                    ND         ND   \[[@B30],[@B31]\]
                           247         IA             HPV107        Portugal           1992             1                    ND         ND   \[[@B30],[@B32]\]
                           247         IA             BK1953        USA                1995             1                    ND         ND   \[[@B30],[@B33]\]
                           250         I              COL           UK                 1965             \-                                   \[[@B30]\]
                           250         I              BK793         Egypt              1961             1                    1          1    \[[@B30],[@B34]\]
                           250         IA             PER34         Spain              1989             1                    ND         ND   \[[@B30],[@B35]\]
                           239         III            ANS46         Australia          1982             1                    1          1    \[[@B30],[@B36]\]
                           239         IIIA           HU25          Brazil             1993             1                    ND         ND   \[[@B30],[@B37]\]
                           239         IIIA           HUSA304       Hungary            1993             1                    ND         ND   \[[@B30],[@B38]\]
  8                        239         IIIA           BK2421        USA                1996             1                    ND         ND   \[[@B30],[@B34]\]
                           8           IVa            USA300        USA                1995-2003        8                    4          9    \[[@B39],[@B40]\]
                           8           IVa            USA500        USA                1995-2003        1                    ND         ND   \[[@B39],[@B40]\]
                           8           IVd            BK2529        USA                1996             1                    ND         ND   \[[@B30],[@B34],[@B39]\]
                           8           IVd            BargII17      USA                1996             1                    ND         ND   \[[@B30],[@B39],[@B41]\]
                           8           IVE            AR43/3330.1   Ireland            1988-2002        1                    1          1    \[[@B42]\]
                           8           IVh            GRE120        Greece             1993             1                    ND         ND   \[[@B39],[@B43]\]
                           72          IVa            USA700        USA                1995-2003        9                    \-         4    \[[@B39],[@B40]\]
                           254         IVh            HAR36         Greece             2002             1                    1          1    \[[@B39],[@B44]\]
                           770         IVb            8/6-3P        Chicago            1996             3                    3          6    \[[@B45]\]
                                                                                                                                             
                           5           I              HAR21         Finland            2002             1                    ND         ND   \[[@B44],[@B46]\]
                           5           I-VAR          PL72          Poland             1991             1                    ND         ND   \[[@B30],[@B47]\]
                           5           II             N315          Japan              1982             8                    4          9    \[[@B18]\]
                           5           II             JP1           Japan              1987             8                    4          9    \[[@B30],[@B48]\]
                           5           II             BK2464        USA                1996             4                    6          2    \[[@B30],[@B49]\]
                           5           II             USA100        USA                1995-2003        3                    3          6    \[[@B40],[@B46]\]
                           5           IVa            BM18          USA                1989             4                    6          2    \[[@B30],[@B39],[@B50]\]
                           5           IVa            FFP311        Portugal           1996             11                   1          7    \[[@B39],[@B51]\]
  5                        5           IVa            HSA49         Portugal           1993             11                   ND         ND   \[[@B39],[@B51]\]
                           5           IVa            HSA74         Portugal           1993             5                    3          3    \[[@B39],[@B51]\]
                           5           IVc            Q2314         Dallas             1996             3                    ND         ND   \[[@B52]\]
                           5           IVc            USA800        USA                1995-2003        1                    ND         ND   \[[@B39],[@B40]\]
                           5           IVc            ARG9          Argentina          1996             11                   7          7    \[[@B39],[@B51]\]
                           5           IVd            JCSC4469      Japan              1982             1                    1          1    \[[@B53]\]
                           5           IVg            M03-68        Korea              2003             3                    ND         ND   \[[@B54]\]
                           5           IV~NT~         COB3          Colombia           1996             6                    5          10   \[[@B30],[@B39],[@B55]\]
                           5           VI             HDE288        Portugal           1996             10                   \-         5    \[[@B51],[@B56]\]
                           5           VI             HUC136        Portugal           1995             10                   \-         5    \[[@B51],[@B56]\]
                           228         I              HAR40         Belgium            1995             2                    3          1    \[[@B44],[@B46]\]
                                                                                                                                             
                           30          IVc            DEN2946       Denmark            2001             1                    1          1    \[[@B39],[@B57]\]
  30                       30          IVc            DEN2294       Denmark            2001             1                    ND         ND   \[[@B39],[@B57]\]
                           36          II             USA200        USA                1995-2003        1                    1          1    \[[@B40],[@B46]\]
                           36          II             HAR24         Finland            2002             1                    ND         ND   \[[@B46],[@B47]\]
                                                                                                                                             
                           22          IVh            HAR22         Finland            2002             9                    \-         4    \[[@B39],[@B44]\]
  22                       22          IVh            HGSA146       Portugal           2003             9                    ND         ND   \[[@B39],[@B58]\]
                           22          IVh            HGSA163       Portugal           2003             9                    ND         ND   \[[@B39],[@B58]\]
                                                                                                                                             
                           45          II             USA600        USA                1995-2003        7                    4          9    \[[@B40],[@B46]\]
  45                       45          IVa            HAR38         Belgium            1995             6                    2          8    \[[@B39],[@B44]\]
                           45          V              WIS           Australia          1995             8                    ND         ND   \[[@B59]\]
                           256         IVa            CA05          Chicago            1999             8                    4          9    \[[@B45]\]
                                                                                                                                             
  1                        1           IVa            MW2           USA                1998             6                    2          10   \[[@B60]\]
                           1           IVa            USA400        USA                1995-2003        6                    2          10   \[[@B39],[@B40]\]
                                                                                                                                             
  80                       80          IVc            DEN2949       Denmark            2001             5                    3          3    \[[@B39],[@B57]\]
                           80          IVc            DEN114        Denmark            2001             5                    1          3    \[[@B39],[@B57]\]
                                                                                                                                             
  Singleton                377         V              HT0184        Greece             2005             6                    2          10   \[[@B61]\]
                           377         V              HT0826        France             2003             6                    ND         ND   \[[@B61]\]

a\) Clonal complexes were determined using the E-burst software <http://saureus.mlst.net/>, last accessed on June 04, 2009.

ND, not determined, -, negative PCR amplification.

###### 

Characteristics and *bla*locus allotypes of MSSA strains used in this study^a)^

  **Clonalcomplex ^b)^**   MLST (ST)   PFGE type   Strain        Origin     Isolation date   *bla*locus alleles        
  ------------------------ ----------- ----------- ------------- ---------- ---------------- -------------------- ---- ----
                           1           G           IPOP38        Portugal   2001             6                    2    10
  1                        188         L           IPOP58        Portugal   2001             6                    2    10
                           573         M           HSJ109        Portugal   1995             6                    2    10
                                                                                                                       
  5                        5           C           HSA29         Portugal   1992-1993        11                   4    7
                           5           C           IPOP41        Portugal   2001             6                    3    6
                                                                                                                       
  8                        8           J           IPOP65        Portugal   2001             8                    2    ND
                           615         E           IPOP32        Portugal   2001             9                    1    4
                                                                                                                       
  9                        9           D           HSJ122        Portugal   1995             12                   1    12
                                                                                                                       
  10                       10          Q           DCC300        Portugal   1996-1997        9                    1    5
                                                                                                                       
  12                       12          X           HSJ130        Portugal   1995             3                    3    6
                           12          X           Draftees728   Portugal   1996-1997        1                    1    1
                                                                                                                       
  15                       15          K           HSA9          Portugal   1992-1993        6                    9    ND
                                                                                                                       
  20                       20          N           HSA47         Portugal   1992-1993        6                    8    11
                                                                                                                       
  22                       22          T           Draftees721   Portugal   1996-1997        6                    3    5
                                                                                                                       
  25                       25          S           HSA76         Portugal   1992-1993        1                    1    1
                                                                                                                       
                           30          A           IPOP37        Portugal   2001             13                   1    1
  30                       34          B           IPOP24        Portugal   2001             6                    ND   ND
                           34          B           IPOP34        Portugal   2001             1                    1    ND
                           NA          B           IPOP26        Portugal   2001             1                    ND   ND
                                                                                                                       
  45                       45          H           HSA19         Portugal   1992-1993        6                    2    10
                           45          H           IPOP56        Portugal   2001             6                    ND   ND
                                                                                                                       
  97                       97          P           IPOP50        Portugal   2001             6                    ND   ND
                                                                                                                       
  121                      121         F           IPOP44        Portugal   2001             10                   1    5
                                                                                                                       
  Singleton                580         R           DCC1185       Portugal   1996-1997        1                    1    1

a\) MSSA strains have been previously characterized by PFGE and MLST\[[@B62]\].

b\) Clonal complexes were determined using the E-burst software <http://saureus.mlst.net/eburst/database.asp>, last accessed on June 04, 2009.

NA, not available; ND, not determined.

Media and growth conditions
---------------------------

Strains were grown overnight at 37°C on tryptic soy agar or tryptic soy broth under aerobic conditions.

DNA isolation
-------------

Total DNA was prepared using the Wizard genomic DNA preparation kit (Promega, Madison, WI, USA), according to the manufacturer\'s recommendations, except for the addition of lysostaphin at 0.5 mg/mL and RNase at 0.3 mg/mL for the lysis step.

DNA amplification and sequencing
--------------------------------

The allelic variation on the β-lactamase locus was evaluated by sequencing internal fragments of *blaZ*and its transcriptional regulators, *blaI*and *blaR1*, amplified by PCR. Based on the available sequence at GenBank (accession number: [X52734](X52734)) for Tn*552*of *S. aureus*, three pairs of primers were designed as follows (5\' → 3\'): blaZ F1, GAT AAG AGA TTT GCC TAT GC; blaZ R1, GCA TAT GTT ATT GCT TGA CC; blaI F1, GCA AGT TGA AAT ATC TAT GG; blaI R1, GAA AGG ATC CAT TTT CTG TAC ACT CTC ATC; blaR1 F1, CAT GAC AAT GAA GTA GAA GC; and blaR1 R1, CTT ATG ATT CCA TGA CAT ACG. The predicted amplicon sizes were 533 bp for *blaZ*, 484 bp for *blaI*and 537 bp for *blaR1*. PCR was performed in a T1 Thermocicler (Biometra) with the following conditions: 94°C for 4 min; 30 cycles of 94°C for 30 s, 55°C for 30 s and 72°C for 1 min; and a final extension at 72°C for 10 min. In each reaction (final volume of 50 μL), 5 ng of chromosomal template, 2.5 U of GoTaq flexi DNA polymerase (Promega), 1× Colorless GoTaq flexi buffer (Promega), 2.5 mM MgCl2 (Promega), 40 μM of each deoxynucleoside triphosphate (dNTPs mixture, Bioron) and 20 pmol of the forward and reverse primers were used. The amplified fragments were purified using a mix of Exonuclease and SAP enzymes. Sequencing of both strands was performed by Macrogen <http://www.macrogen.com> or STAB Vida <http://www.stabvida.com>.

DNA sequences analysis and phylogenetic tree reconstruction
-----------------------------------------------------------

DNA sequencing raw data analysis and multi-sequence alignments were performed using the DNA Star software package (Lasergene). For the multi-sequence alignments, the Clustal W algorithm was used. In order to maximize sequence reads, raw sequences for *blaZ*and *blaR1*were trimmed immediately after the primer sequences keeping the reading frame. As the reverse primer for *blaI*(BlaI R1) is located outside of the coding region, the 3\' end of the sequence was trimmed at the end of the coding region. For each gene, allotypes were defined taking as reference the extant sequences of the *bla*locus of Tn*552*, which were assigned to allotype 1.

Phylogenetic and molecular evolutionary analyses were conducted using *MEGA*version 4 \[[@B25]\] and the resultant phylogenetic trees were obtained using the neighbour-joining (NJ) method with bootstrap analysis using 1000 replicates. In order to evaluate the diversity of the *bla*locus, the Simpson\'s indexes of diversity (SID) were calculated \[[@B26],[@B27]\] for each locus using the online tool available at <http://www.comparingpartitions.info.> To estimate selection pressure acting on the *bla*locus, we computed the dN/dS ratios for the three genes. The dN/dS ratios were computed for all pairs of alleles with more than 1% substitutions, in order to give an estimate of the divergence of the alleles while excluding those pairs that, being too similar, would give anomalous dN/dS ratios. The dN/dS ratios were computed by Model Averaging, as described in \[[@B28]\] and implemented in the KaKs_Calculator application \[[@B29]\]. This approach fits a set of models by maximum likelihood and then computes the weighted average of the models using a second-order Akaike Information Criterion (AICC).

Nucleotide sequence accession numbers
-------------------------------------

All nucleotide sequences determined in this study were deposited in Genbank under accession numbers [GQ980053](GQ980053)-[GQ980139](GQ980139) (*blaZ*alleles), [GQ980140](GQ980140)-[GQ980187](GQ980187) (*blaI*alleles) and [GQ980188](GQ980188)-[GQ980236](GQ980236) (*blaR1*alleles).

Results
=======

The allelic variation in the β-lactamase locus (*bla*) was evaluated by sequencing internal fragments of *blaZ*, *blaI*and *blaR1*genes in a representative collection of international epidemic MRSA clones and also, for comparative purposes, in a diverse collection of MSSA strains.

*blaZ*allelic variability
-------------------------

Thirteen different *blaZ*allotypes were identified within our collection, which comprised 54 MRSA and 24 MSSA (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}, respectively). Although seven alleles were common to MRSA and MSSA strains, we found four alleles present in MRSA strains only and two present in MSSA strains only. Moreover, the relative frequencies of each allele were different among MRSA and MSSA strains (Table [3](#T3){ref-type="table"}); for instance, *blaZ*allotype 1 was dominant in MRSA strains accounting for 43% (23 out of 54) of the isolates whereas in MSSA it accounted for 21% (5 out of 24) of the isolates, and *blaZ*allotype 6 was present in 11% (6 out 54) of MRSA but was dominant among MSSA accounting for 46% (11 out 24) of the isolates. The diversity of *blaZ*gene as measured by the Simpson index of diversity (SID) was higher for the MRSA collection than for MSSA, although not statistically significant due to the partial overlapping of the confidence intervals (SID = 79.18, 95%CI 69.6-88.8 *vs*SID = 76.09, 95%CI 61.3-90.9, respectively) - see Table [4](#T4){ref-type="table"}. Within the length of *blaZ*region analyzed (492 nucleotides), we detected 43 unique single-nucleotide polymorphisms (SNP) and on average, each *blaZ*allele has 12.4 SNP comparing to the prototype *blaZ*sequence of Tn*552*(allele 1) - see Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}. Overall, *blaZ*alleles were more variable in MSSA than in MRSA (14.7 and 11.4 SNP/allele, respectively). As illustrated by the allelic frequency distribution per MRSA lineage (Figure [1](#F1){ref-type="fig"}) or the cluster tree of the thirteen *blaZ*alleles found in our collections (Figure [2](#F2){ref-type="fig"}), there is no clustering according to genetic lineages, as defined by MLST sequence type and SCC*mec*type, or MSSA/MRSA phenotype; i.e. the same allele could be detected in different genetic lineages or among MRSA and MSSA, and the same lineage could be characterized by several alleles. In addition, there was also no clear clustering of *blaZ*allotypes according to geographic origin or isolation date of the MRSA isolates (see Table [1](#T1){ref-type="table"}).

###### 

Characteristics of *bla*locus alleles

  Gene          Allele No.   Frequency   **SNP**^**c)**^   Amino acid substitutions                 
  ------------- ------------ ----------- ----------------- -------------------------- ---- --- ---- ---
                1            0.43        0.21              0                          0    0   0    0
                2            0.02        0                 1                          0    0   1    1
                3            0.07        0.04              9                          4    2   2    0
                4            0.04        0                 9                          4    2   3    0
                5            0.06        0                 7                          2    2   3    0
                6            0.11        0.46              13                         8    2   3    0
  ***blaZ***    7            0.02        0                 12                         6    2   4    0
                8            0.10        0.04              11                         6    2   3    0
                9            0.07        0.08              20                         9    2   7    0
                10           0.04        0.04              19                         8    2   7    0
                11           0.06        0.04              24                         11   3   8    0
                12           0           0.04              24                         11   2   8    0
                13           0           0.04              12                         7    2   3    0
                                                                                                    
                1            0.33        0.45              0                          0    0   0    0
                2            0.15        0.25              6                          5    0   1    0
                3            0.19        0.15              1                          0    0   1    0
                4            0.19        0.05              4                          3    0   1    0
  ***blaI***    5            0.04        0                 7                          5    0   2    0
                6            0.07        0                 4                          3    0   1    0
                7            0.04        0                 5                          4    0   1    0
                8            0           0.05              3                          1    1   1    0
                9            0           0.05              1                          0    0   1    0
                                                                                                    
                1            0.26        0.24              0                          0    0   0    0
                2            0.07        0                 19                         9    4   6    0
                3            0.10        0                 18                         7    4   6    0
                4            0.07        0.06              35                         15   9   10   0
                5            0.07        0.18              35                         15   7   11   0
                6            0.07        0.12              17                         6    4   6    0
  ***blaR1***   7            0.07        0.06              24                         10   7   7    0
                8            0.03        0                 33                         12   6   12   0
                9            0.16        0                 31                         11   6   11   0
                10           0.13        0.24              32                         12   6   11   0
                11           0           0.06              20                         9    5   7    0
                12           0           0.06              34                         16   6   10   0

a\) The total number of MRSA strains whose *blaZ*, *blaI*and *blaR1*genes were analyzed is 54, 27 and 31, respectively.

b\) The total number of MSSA strains whose *blaZ*, *blaI*and *blaR1*genes were analyzed is 24, 20 and 17, respectively.

c\) For each allele, the SNP were counted taking as reference Tn*552 bla*sequences (allele 1).

###### 

Comparative analysis of the allelic variation in *bla*locus for MRSA and MSSA strains

                           No. isolates   No. alleles   Simpson\'s   Unique SNP   SNP/allele (average)   Mutations per allele (average)   dN/dS                            
  ---------- ------------- -------------- ------------- ------------ ------------ ---------------------- -------------------------------- ------- ----- ----- ----- ------ ------
             ***blaZ***    54             11            79.2         69.6-88.8    41                     11.4                             5.3     1.7   3.7   0.1   0.21   0.11
  **MRSA**   ***blaI***    27             7             82.1         74.6-89.5    10                     3.9                              2.9     0     1.0   0     0.11   0.05
             ***blaR1***   31             10            88.8         83.2-94.4    60                     24.4                             9.7     5.3   8.0   0     0.24   0.11
                                                                                                                                                                           
             ***blaZ***    24             9             76.1         61.3-90.9    35                     14.7                             7.1     1.9   4.6   0     0.17   0.04
  **MSSA**   ***blaI***    20             6             74.2         60.5-87.9    9                      2.5                              1.5     0.2   0.8   0     0.08   0.03
             ***blaR1***   17             8             88.2         81.2-95.3    61                     24.6                             10.4    5.5   7.8   0     0.24   0.10
                                                                                                                                                                           
             ***blaZ***    78             13            81.1         75.0-87.3    43                     12.4                             5.8     1.8   4.0   0.1   0.20   0.10
  **All**    ***blaI***    47             9             78.4         71.0-85.9    13                     3.4                              2.3     0.1   1.0   0     0.10   0.04
             ***blaR1***   48             12            88.5         84.0-93.0    65                     24.8                             10.2    5.3   8.1   0     0.25   0.10

ID, index of diversity; CI, confidence interval; SNP, single-nucleotide polymorphism; Conserv., conservative; St. dev., standard deviation

![***blaZ*allotype frequency per MRSA lineage as defined by MLST clonal cluster**.](1471-2180-11-76-1){#F1}

![**Cluster tree of *blaZ*gene allotypes found in the MRSA and MSSA collections**. The tree was constructed with the neighbor-joining (NJ) method. In each branch is shown the corresponding bootstrap NJ values, taken over 1000 replicates, which assigns confidence values for the groupings in the tree. For each allele, it is indicated the collection(s) (MRSA or MSSA) and genetic lineage (clonal cluster) where it was found.](1471-2180-11-76-2){#F2}

The BlaZ variability in the MRSA and MSSA strains at the protein level was evaluated by comparison of the deduced amino acid sequence of all alleles against the deduced amino acid sequence for the BlaZ of Tn*552*. Overall, the deduced amino acid sequences of *blaZ*alleles from the MRSA and MSSA strains revealed on average 5.8 silent mutations, 1.8 conservative missense mutations and 4 non-conservative missense mutations per allotype (see Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}). For MRSA strain HAR40, a nonsense mutation at Gln76 was detected which presumably originates a non-functional truncated BlaZ protein. As this strain was positive for the nitrocefin test, the DNA extraction and the *blaZ*sequencing were repeated and the nonsense mutation was confirmed. No frameshift mutations were found in *blaZ*allotypes.

Allelic variability of *blaZ*regulatory genes
---------------------------------------------

Based on the *blaZ*variability analysis, we selected 51 representative strains to further characterize the variability in the *blaZ*regulatory genes, *blaI*and *blaR1*. Some of these strains failed in the amplification of one of the *blaZ*regulatory genes (see Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}).

Within the length of *blaI*region analyzed (351 nucleotides), we detected 13 unique SNP, which account for the nine *blaI*allotypes detected (see Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}). Four of the nine *blaI*allotypes were present in both MRSA and MSSA, while three *blaI*allotypes were found in MRSA strains only and two in MSSA only. The SID was higher for MRSA than for MSSA although not statistically significant (SID = 82.1, 95%CI 74.6-89.5 *vs*SID = 74.2, 95%CI 60.5-87.9, respectively) (Table [4](#T4){ref-type="table"}). On average, each *blaI*allele has 3.4 SNP comparing to the prototype *blaI*sequence of Tn*552*(allele 1), and *bla*I alleles were on average more polymorphic for MRSA than for MSSA (3.9 *vs*2.5 SNP per allele, respectively) - see Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}.

Within the length of *blaR1*region analyzed (498 nucleotides), we detected 65 unique SNP, which account for the 12 *blaR1*allotypes detected (see Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}). Six of the 12 *blaR1*allotypes were present in both MRSA and MSSA, while four *blaR1*allotypes were unique for MRSA strains and two were characteristic of MSSA strains. The SID values were virtually identical for both MRSA and MSSA (SID = 88.8, 95%CI 83.2-94.4 *vs*SID = 88.2, 95%CI 81.2-95.3, respectively) (Table [4](#T4){ref-type="table"}). On average, each *blaR1*allele has 24.8 SNP comparing to the prototype *blaR1*sequence of Tn*552*(allele 1), with no significant differences between MRSA and MSSA (24.4 and 24.6 SNP/allele, respectively) - see Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}.

In agreement with what was observed for the *blaZ*gene, the cluster trees of *blaI*and *blaR1*alleles found in our collections also showed no clustering according to MSSA/MRSA phenotype or genetic lineages (Figures [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}). For those strains in which the alleles of the three genes were determined, we constructed a cluster tree with the concatenated sequences - see Figure [5](#F5){ref-type="fig"}. In spite of the relatively low number of allelic profiles, there was still no clear clustering of *bla*allotypes according to MSSA/MRSA phenotype or lineage, as the same allelic profile was present in different genetic lineages (e.g. profile 8/4/9 present in clonal complexes 5, 8 and 45) and, the same genetic lineage was characterized by profiles from different brunches (e.g. clonal cluster 8 characterized by profiles 8/4/9, 1/1/1, 3/3/6, etc.).

![**Cluster tree of *blaI*gene allotypes found in the MRSA and MSSA collections**. See Figure 2 legend for details.](1471-2180-11-76-3){#F3}

![**Cluster tree of *blaR1*allotypes found in the MRSA and MSSA collections**. See Figure 2 legend for details.](1471-2180-11-76-4){#F4}

![**Cluster tree of the concatenated *blaZ-blaR1-blaI*sequences found in the MRSA and MSSA collections**. See Figure 2 legend for details.](1471-2180-11-76-5){#F5}

The BlaI and BlaR1 variabilities at the protein level in the MRSA and MSSA strains were evaluated by comparison of the deduced amino acid sequence of all alleles against the corresponding deduced amino acid sequences of Tn*552*(see Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}). Overall, the deduced amino acid sequences of the *blaI*alleles revealed on average 2.3 silent mutations, 0.1 conservative missense mutations and 1 non-conservative missense mutation per allotype. The deduced amino acid sequences of the *blaR1*alleles showed on average 10.2 silent mutations, 5.3 conservative missense mutations and 8.1 non-conservative missense mutations per allotype. None of the SNP detected within the *blaI*or *blaR1*resulted in nonsense or frameshift mutations.

Selection pressure acting on the *bla*locus
-------------------------------------------

Based on the allelic data obtained, we computed the dN/dS ratios as estimates for the selective pressure acting on the *bla*locus. The dN/dS ratios were computed for all pairs of alleles differing more than 1%, in order to give an estimate of the allelic divergence, excluding the anomalous dN/dS ratios of those pairs being very similar. The average of the obtained dN/dS values and respective standard deviations are summarized in Table [4](#T4){ref-type="table"}. The dN/dS values for the three genes in the MRSA, MSSA and MRSA/MSSA partitions were well below 1 (between 0.08 and 0.25 with standard deviations between 0.05 and 0.1), which suggests a negative or purifying selection acting on the *bla*locus. In agreement with the average number of SNP per allele, the dN/dS ratios were significantly higher for the *blaR1*gene (0.24 - 0.25) and lower for *mecI*(0.08 - 0.11).

Discussion
==========

The rationale for this study comes from several observations strongly suggesting a role of *bla*genes in the acquisition, stabilization and regulation of *mecA*gene, the central element of \"broad-spectrum\" β-lactam resistance characteristic of MRSA strains. The purpose of this study was to evaluate the allelic variability of the *bla*locus in a representative collection of international epidemic MRSA clones and also, for comparative purposes, in a diverse collection of MSSA strains, in an attempt to establish evolutionary correlations between *bla*allotypes and β-lactam resistance phenotypes (i.e. between MRSA and MSSA), SCC*mec*types (i.e. polymorphisms in the *mecA*regulatory locus) and/or genetic lineages.

MRSA lineages are much less diverse than MSSA lineages in terms of their genome content, a consequence of their more recent evolutionary history \[[@B19],[@B20]\] and, apparently, also due to some \"host barrier\" to the SCC*mec*acquisition \[[@B13]\]. These differences in genetic background variability were well illustrated in our collections since the international MRSA collection comprised eight lineages as defined by MLST clonal complexes, whereas in the smaller and local MSSA collection 15 lineages were represented.

In contrast to the genetic background diversity, we could not detect significant differences between MSSA and MRSA in terms of the *bla*locus allelic variability. Actually, there were disparate subtle differences in terms of number of allotypes and number of point mutations per allotype: e.g. 11 *vs*9 *blaZ*allotypes and 11.4 *vs*14.7 SNP/allele in MRSA and MSSA, respectively. These subtle differences may reflect the more ancient evolutionary history of MSSA or a selective pressure to improve the *bla*locus activity in these strains. That is to say, although fewer *bla*types have been retained by the natural selection in MSSA, on average, these allotypes seem to have accumulated more adaptive mutations, in comparison to MRSA strains. In particular for *blaZ*, for which differences in terms of number of alleles and SNP/allele were more significant, the presence of the alternative β-lactam resistance mechanism mediated by the *mecA*gene in MRSA strains might have allowed a release in the selective pressure to keep *blaZ*with optimal activity, in contrast to MSSA, which rely only on *blaZ*-mediated resistance to β-lactams.

No correlation could be established between *bla*allotypes and strain backgrounds, β-lactam resistance phenotypes, strain origin and/or isolation dates, indicating that *bla*genes have evolved independently from *S. aureus*clonal lineages. This is particularly striking for MRSA strains, which have a very strong clonal structure. These observations may be explained either by differences in evolutionary clock speeds between the genetic background and the *bla*locus or may result from the horizontal transfer of *bla*genes between different lineages, which are usually integrated in mobile elements (plasmids and composite transposons). Interestingly, based on the characterization of a collection of several staphylococcal species, Olsen *et al*, suggested that there is little exchange of *bla*genes between strains or species \[[@B14]\], which somehow contradicts our findings. In our study, the most parsimony explanation for the presence of the same *bla*type in different genetic lineages either MRSA or MSSA or the presence of several *bla*types in the same lineage, is indeed a high frequency for the horizontal transfer of *bla*genes across *S. aureus*clonal clusters.

In spite of the lack of evolutionary links between *bla*allotypes and genetic lineages, our data strongly suggests a selective pressure to keep the *bla*locus fully functional, as illustrated by the calculated average dN/dS values well below 1. This observation is valid even on MRSA for which one could expect the accumulation of nonsense or frameshift mutations that would render the *bla*locus non-functional, due to presence of the *mecA*gene. Actually, the majority of the mutational events detected in this study were either silent or neutral mutations, being the *blaR1*the gene with the highest mutational rate and the *blaI*the one with the lowest. The increased allelic variability detected for *blaR1*(in terms of number of alleles, Simpson\'s index of diversity, average SNP/allele, and dN/dS values) may suggest that this sensor-inducer gene is the primary target for the evolutionary adaptive mechanisms in the *bla*locus, presumably to improve the induction efficiency of *blaZ*expression or even *mecA*expression, in the case of MRSA strains with no functional *mecI-mecR1*regulatory system. In contrast, the relatively lower variability of the much smaller *blaI*gene, may suggest a fine-tuned repressor activity and a selective pressure to maintain the repressor activity; i.e to maintain the *blaZ*expression inducible.

Despite the cross-resistance to virtually all β-lactam antibiotics provided by *mecA*, most contemporary MRSA strains still carry, besides the SCC*mec*element, the β-lactamase locus. This might be due to the fact that not enough time has elapsed since the *mecA*acquisition for MRSA strains start loosing the *bla*genes, because there is a little or no fitness cost associated to the *bla*genes, or because these genes may be linked to other positively selected genes (e.g. the cadmium resistance genes present in some β-lactamase plasmids). Alternatively, the *bla*locus may be involved in the \"domestication\" of the *mecA*gene, as *bla*genes have been shown to stabilize the *in vitro mecA*acquisition \[[@B12],[@B13]\] and efficiently control *mecA*transcription \[[@B9],[@B10]\], explaining the \"retention\" of a functional *bla*regulatory system by most contemporary MRSA strains \[[@B8]\]. Interestingly, as no correlation could be established between *bla*allotypes and SCC*mec*types, which have polymorphisms in the *mecA*regulatory locus, this maintenance of functional *blaI-blaR1*genes seems to be independent of the functional status of the *mecA*\"natural\" regulators *mecI-mecR1*.

Concerning the maintenance of a functional *blaZ*gene in MRSA strains one can speculate that, even in the presence of *mecA*, it might be useful for the bacteria to keep *blaZ*as a \"first-line defense\" against β-lactams. In fact, first generation β-lactams (i.e. penicillins) are still widely prescribed either empirically or for the treatment of specific infections (e.g. streptococcal infections). Moreover, penicillins have also been widely used prophylactically in the livestock industry. This means that, both in the nosocomial and community settings, MRSA are still exposed to penicillins and, under these circumstances, expression of β-lactamase is enough for survival under antibiotic pressure. From a physiological perspective, this ability to choose between the expression of two resistance genes may be advantageous for the bacteria since the expression of β-lactamase is likely to impose a smaller fitness cost than the expression of PBP2a. In fact, besides being much smaller than PBP2a (257 *vs*668 amino acids), BlaZ is a secreted enzyme whereas PBP2a is a transpeptidase protein, which must be incorporated into the complex cell-wall metabolism.

Conclusion
==========

In this study we have evaluated the allelic variation of the *bla*locus in MRSA and MSSA clinical strains. Although no correlation between *bla*allotypes and genetic lineages, SCC*mec*types and β-lactam resistance phenotypes could be established, we provided evidence for the existence of a selective pressure to maintain the *bla*system fully functional even on MRSA strains and that the sensor-inducer gene *blaR1*is the primary target for the accumulation of adaptive mutations in the *bla*locus.
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